CELF2 is a candidate prognostic and immunotherapy biomarker in triple-negative breast cancer and lung squamous cell carcinoma: A pan-cancer analysis.
Libo Wang,Zaoqu Liu,Long Liu,Chunguang Guo,Dechao Jiao,Lifeng Li,Jie Zhao,Xinwei Han,Yuling Sun +8 more
Reads0
Chats0
TLDR
Wang et al. as mentioned in this paper found that increased CELF2 expression was associated with better prognosis and superior TIIC infiltration and ICM expression, particularly in BRCA and LUSC.Abstract:
CUGBP Elav-like family member 2(CELF2) plays crucial roles in the development and activation of T cell. However, the impacts of CELF2 on tumour-infiltrating immune cells (TIICs) and clinical outcomes of tumours remain unclear. In this study, we found that elevated CELF2 expression was markedly correlated with prolonged survival in multiple tumours, particularly in breast and lung cancers. Notably, CELF2 only impacted the prognosis of triple-negative breast cancer (TNBC) with lymph node metastasis. Further investigation showed CELF2 expression was positively correlated with the infiltration abundance of dendritic cells (DCs), CD8+ T cells and neutrophils in breast invasive carcinoma (BRCA) and DCs in lung squamous cell carcinoma (LUSC). CELF2 also had strong correlations with markers of diverse TIICs such as T cells, tumour-associated macrophages and DCs in BRCA and LUSC. Importantly, CELF2 was significantly associated with plenty of immune checkpoint molecules (ICMs) and outperformed five prevalent biomarkers including PD-1, PD-L1, CTLA-4, CD8 and tumour mutation burden in predicting immunotherapeutic responses. Immunohistochemistry also revealed lower protein levels of CELF2 in TNBC and LUSC compared to normal tissues, and patients with high expression showed significantly prolonged prognosis. In conclusion, we demonstrated that increased CELF2 expression was closely related to better prognosis and superior TIIC infiltration and ICM expression, particularly in BRCA and LUSC. CELF2 also performed well in evaluating the immunotherapeutic efficacy, suggesting CELF2 might be a promising biomarker.read more
Citations
More filters
Journal ArticleDOI
CELF Family Proteins in Cancer: Highlights on the RNA-Binding Protein/Noncoding RNA Regulatory Axis
TL;DR: A review of CELF protein regulation and their functional consequences in cancer physiology can be found in this paper, where the authors outline some mechanisms and their effects on CELF proteins, particularly via noncoding RNAs.
Journal ArticleDOI
Ferroptosis Mediation Patterns Reveal Novel Tool to Implicate Immunotherapy and Multi-Omics Characteristics in Bladder Cancer
Jing-cheng Liu,Zheng Zhang,Wei Zhang,Lingfeng Meng,Jiawen Wang,Zhengtong Lv,Haoran Xia,Meng Wu,Yaoguang Zhang,Jianye Wang +9 more
TL;DR: The quantification of ferroptosis mediation patterns in individual samples served as a promising tool for predicting patient survival outcomes; immune cell infiltration abundance; tumour mutation burden; oncogenic mutation status and tumour grade, stage and molecular subtypes.
Journal ArticleDOI
Integrated Analysis of Tumor Mutation Burden and Immune Infiltrates in Hepatocellular Carcinoma
TL;DR: Immune cell infiltration analysis revealed that the degree of central memory T-cell (Tcm) infiltration may be correlated with the HCC process, and NCBP2 can be used as diagnostic markers of HCC, and immune cell infiltration plays an important role in the occurrence and progression of H CC.
Posted ContentDOI
Comprehensive analysis of the relevance of the CELF gene family to prognosis and immune infiltration in brain glioma
TL;DR: The CELF gene family is a set of highly conserved genes that encode a family of RNA-binding proteins in human tissues and participate in posttranscriptional modifications as discussed by the authors .
Posted ContentDOI
Circular RNA hsa_circ_0006421 inhibits hepatocellular carcinoma by acting as a ceRNA targeting miR-134-5p/CELF2 pathway
TL;DR: In this article , the effects of hsa-circ_0006421 on hepatocellular carcinoma (HCC) cells were investigated using qRT-PCR and Western blot to detect the expression of miR-134-5p, CELF2, and hsa_circ_ 0006421.
References
More filters
Journal ArticleDOI
Cancer Statistics, 2021.
TL;DR: In the United States, the cancer death rate has dropped continuously from its peak in 1991 through 2018, for a total decline of 31%, because of reductions in smoking and improvements in early detection and treatment as mentioned in this paper.
Journal ArticleDOI
GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses.
TL;DR: GEPIA (Gene Expression Profiling Interactive Analysis) fills in the gap between cancer genomics big data and the delivery of integrated information to end users, thus helping unleash the value of the current data resources.
Journal ArticleDOI
TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells
Taiwen Li,Taiwen Li,Jingyu Fan,Binbin Wang,Nicole Traugh,Qianming Chen,Jun Liu,Bo Li,X. Shirley Liu,X. Shirley Liu +9 more
TL;DR: Tumor Immune Estimation Resource (TIMER) is presented to comprehensively investigate molecular characterization of tumor-immune interactions and provides a user-friendly web interface for dynamic analysis and visualization of these associations, which will be of broad utilities to cancer researchers.
Journal ArticleDOI
Genomic and transcriptomic features of response to anti-pd-1 therapy in metastatic melanoma
Willy Hugo,Jesse M. Zaretsky,Lu Sun,Chunying Song,Blanca Homet Moreno,Siwen Hu-Lieskovan,Beata Berent-Maoz,Jia Pang,Bartosz Chmielowski,Grace Cherry,Elizabeth Seja,Shirley H. Lomeli,Xiangju Kong,Mark C. Kelley,Jeffrey A. Sosman,Douglas B. Johnson,Antoni Ribas,Roger S. Lo +17 more
TL;DR: It is found that overall high mutational loads associate with improved survival, and tumors from responding patients are enriched for mutations in the DNA repair gene BRCA2, suggesting that attenuating the biological processes that underlie IPRES may improve anti-PD-1 response in melanoma and other cancer types.
Journal ArticleDOI
TIMER2.0 for analysis of tumor-infiltrating immune cells
Taiwen Li,Jingxin Fu,Jingxin Fu,Zexian Zeng,David M. Cohen,Jing Li,Qianming Chen,Bo Li,X. Shirley Liu +8 more
TL;DR: TIMER2.0 (http://timer.cistrome.org/) provides more robust estimation of immune infiltration levels for The Cancer Genome Atlas (TCGA) or user-provided tumor profiles using six state-of-the-art algorithms.